LAVA Therapeutics NV logo

LAVA Therapeutics NVNASDAQ: LVTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Netherlands

IPO:

26 March 2021

Next earnings report:

22 November 2024

Last dividends:

N/A

Next dividends:

N/A
$41.60 M
-78%vs. 3y high
32%vs. sector
-vs. 3y high
-vs. sector
-54%vs. 3y high
38%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | 20 min ago
$1.58+$0.10(+6.89%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

LVTX Latest News

4 Stocks Under $5 To Buy Now
247wallst.com08 August 2024 Sentiment: NEUTRAL

Are you looking for stocks to buy with low price tags?

All You Need to Know About LAVA Therapeutics (LVTX) Rating Upgrade to Strong Buy
zacks.com22 July 2024 Sentiment: POSITIVE

LAVA Therapeutics (LVTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
globenewswire.com20 June 2024 Sentiment: POSITIVE

UTRECHT, The Netherlands and PHILADELPHIA, June 20, 2024 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (NASDAQ: LVTX, “LAVA”), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody® platform of bispecific gamma delta T cell engagers, today announced that Stephen Hurly, President and Chief Executive Officer of LAVA Therapeutics, will present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference.

LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
GlobeNewsWire06 September 2023 Sentiment: POSITIVE

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 06, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will participate in a virtual fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference which will be available on Monday, September 11, 2023 at 7:00 am ET.

LAVA Therapeutics N.V. (LVTX) Reports Q2 Loss, Tops Revenue Estimates
Zacks Investment Research22 August 2023 Sentiment: NEUTRAL

LAVA Therapeutics N.V. (LVTX) came out with a quarterly loss of $0.48 per share in line with the Zacks Consensus Estimate.

Lava (LVTX) Discontinues Hematological Tumor Study, Shares Fall
Zacks Investment Research15 June 2023 Sentiment: NEGATIVE

Lava (LVTX) falls 10% due to its decision to discontinue the study on LAVA-051, which is being evaluated for multiple hematological tumors. The company shifts focus to LAVA-1207 in the prostate cancer study.

What type of business is LAVA Therapeutics NV?

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.

What sector is LAVA Therapeutics NV in?

LAVA Therapeutics NV is in the Healthcare sector

What industry is LAVA Therapeutics NV in?

LAVA Therapeutics NV is in the Biotechnology industry

What country is LAVA Therapeutics NV from?

LAVA Therapeutics NV is headquartered in Netherlands

When did LAVA Therapeutics NV go public?

LAVA Therapeutics NV initial public offering (IPO) was on 26 March 2021

What is LAVA Therapeutics NV website?

https://www.lavatherapeutics.com

Is LAVA Therapeutics NV in the S&P 500?

No, LAVA Therapeutics NV is not included in the S&P 500 index

Is LAVA Therapeutics NV in the NASDAQ 100?

No, LAVA Therapeutics NV is not included in the NASDAQ 100 index

Is LAVA Therapeutics NV in the Dow Jones?

No, LAVA Therapeutics NV is not included in the Dow Jones index

When was LAVA Therapeutics NV the previous earnings report?

No data

When does LAVA Therapeutics NV earnings report?

The next expected earnings date for LAVA Therapeutics NV is 22 November 2024